Skip to main content
Equibles

Erin Lavelle

Board Member

Jade Biosciences, Inc. (JBIO)

Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.

About Erin Lavelle

Erin Lavelle is recorded as Board Member at Jade Biosciences, Inc. (JBIO). Earlier roles on record: Board Member at Neurogene Inc. (NGNE) until December 18, 2023. Jade Biosciences, Inc. reported in an 8-K filed May 1, 2025 that Erin Lavelle was appointed Board of Directors, effective April 28, 2025. Neurogene Inc. reported in an 8-K filed December 19, 2023 that Erin Lavelle resigned as director, effective December 18, 2023.

“On April 28, 2025, the Board decreased its size from seven to six members and appointed the following six individuals to the Board: Eric Dobmeier, Christopher Cain, Tom Frohlich, Tomas Kiselak, Lawrence Klein and Erin Lavelle.”
Jade Biosciences, Inc. Form 8-K, filed May 1, 2025 · Read the filing
“On the Separation Date, Martin Babler, M. Cantey Boyd, Erin Lavelle and Todd Simpson resigned from Neoleukin's board of directors and its committees on which they respectively served, which resignations were not the result of any disagreements with the Company relating to the Company's operations, policies or practices.”
Neurogene Inc. Form 8-K, filed December 19, 2023 · Read the filing

Summary generated from SEC filings and earnings-call records held by Equibles.

Affiliation history

Recorded current and former roles; source labels appear when available.

Company network

Recorded roles and call appearances connecting this person to public companies.

Leadership on record at Jade Biosciences, Inc.

Other people whose current roles at this company are on record from its filings.

Recent activity

Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.